Assessing the Age Specificity of Infection Fatality Rates for Covid-19: Systematic Review, Meta-Analysis, & Public Policy Implications

To assess age-specific infection fatality rates (IFRs) for COVID-19, we have conducted a systematic review of seroprevalence studies as well as countries with comprehensive tracing programs. Age-specific IFRs were computed using the prevalence data in conjunction with reported fatalities four weeks after the midpoint date of each study, reflecting typical lags in fatalities and reporting. Using metaregression procedures, we find a highly significant log-linear relationship between age and IFR for COVID-19. The estimated age-specific IFRs are very low for children and younger adults but increase progressively to 0.4% at age 55, 1.3% at age 65, 4.2% at age 75, and 14% at age 85. About 90% of the geographical variation in population IFR is explained by differences in age composition of the population and age-specific prevalence. These results indicate that COVID-19 is hazardous not only for the elderly but also for middle-aged adults. Moreover, the population IFR for COVID-19 should not be viewed as a fixed parameter but as intrinsically linked to the age-specific pattern of infections. Consequently, public health measures to protect vulnerable age groups could substantially decrease total deaths.

[1]  N. Akilli,et al.  Prevalence of Asymptomatic SARS-CoV-2 Infection , 2021, Annals of Internal Medicine.

[2]  G. Chertow,et al.  Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study , 2020, The Lancet.

[3]  A. Giacomelli,et al.  Seroprevalence of SARS-CoV-2 significantly varies with age: Preliminary results from a mass population screening , 2020, Journal of Infection.

[4]  H. Kamel,et al.  Seroprevalence of Antibodies to SARS-CoV-2 in US Blood Donors , 2020, medRxiv.

[5]  A. Trkola,et al.  Variation in SARS-CoV-2 seroprevalence in school-children across districts, schools and classes , 2020, medRxiv.

[6]  S. Stramer,et al.  Change in Donor Characteristics and Antibodies to SARS-CoV-2 in Donated Blood in the US, June-August 2020. , 2020, JAMA.

[7]  P. Myles,et al.  A dual antigen ELISA allows the assessment of SARS-CoV-2 antibody seroprevalence in a low transmission setting , 2020, medRxiv.

[8]  S. Rigatti,et al.  SARS-CoV-2 Antibody Prevalence and Association with Routine Laboratory Values in a Life Insurance Applicant Population , 2020, medRxiv.

[9]  Christina C. Chang,et al.  High Seroprevalence of Anti-SARS-CoV-2 Antibodies in Chelsea, Massachusetts , 2020, The Journal of infectious diseases.

[10]  Jan,et al.  Risk Factors for COVID-19: Community Exposure and Mask-Wearing , 2020, SSRN Electronic Journal.

[11]  S. Ladhani,et al.  Seroprevalence of SARS-CoV-2 antibodies in children: a prospective multicentre cohort study , 2020, Archives of Disease in Childhood.

[12]  C. Yiannoutsos,et al.  Infection Fatality Ratios for COVID-19 Among Noninstitutionalized Persons 12 and Older: Results of a Random-Sample Prevalence Study , 2020, Annals of Internal Medicine.

[13]  A. Gylfason,et al.  Humoral Immune Response to SARS-CoV-2 in Iceland , 2020, The New England journal of medicine.

[14]  P. Katzmarzyk,et al.  Racial and workplace disparities in seroprevalence of SARS-CoV-2 in Baton Rouge, Louisiana, July 15-31, 2020 , 2020, medRxiv.

[15]  G. Kochs,et al.  Prevalence of SARS-CoV-2 Infection in Children and Their Parents in Southwest Germany , 2020, JAMA pediatrics.

[16]  M. Breteler,et al.  Seroprevalence and correlates of SARS-CoV-2 neutralizing antibodies: Results from a population-based study in Bonn, Germany , 2020, medRxiv.

[17]  D. Cummings,et al.  Age-specific mortality and immunity patterns of SARS-CoV-2 infection in 45 countries , 2020, medRxiv.

[18]  M. Ranjan,et al.  High SARS-CoV-2 Seroprevalence in Children and Adults in the Austrian Ski Resort Ischgl , 2020, medRxiv.

[19]  M. Peluso,et al.  Universal PCR and antibody testing demonstrate little to no transmission of SARS-CoV-2 in a rural community , 2020, medRxiv.

[20]  M. Dake,et al.  Detection, prevalence, and duration of humoral responses to SARS-CoV-2 under conditions of limited population exposure , 2020, medRxiv.

[21]  C. Donnelly,et al.  Antibody prevalence for SARS-CoV-2 in England following first peak of the pandemic: REACT2 study in 100,000 adults , 2020, medRxiv.

[22]  Jose L. Paniagua,et al.  SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study , 2020, medRxiv.

[23]  A. Ko,et al.  Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study , 2020, medRxiv.

[24]  D. Buckeridge,et al.  SeroTracker: a global SARS-CoV-2 seroprevalence dashboard , 2020, The Lancet Infectious Diseases.

[25]  S. Merler,et al.  Age-specific SARS-CoV-2 infection fatality ratio and associated risk factors, Italy, February to April 2020 , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[26]  E. Petinaki,et al.  Repeated leftover serosurvey of SARS-CoV-2 IgG antibodies, Greece, March and April 2020 , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[27]  C. Steves,et al.  Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England , 2020, Journal of Infection.

[28]  E. Price-Haywood,et al.  Seroprevalence of SARS-CoV-2 and Infection Fatality Ratio, Orleans and Jefferson Parishes, Louisiana, USA, May 2020 , 2020, Emerging infectious diseases.

[29]  P. Kelleher,et al.  High Prevalence of Asymptomatic COVID-19 Infection in Hemodialysis Patients Detected Using Serologic Screening. , 2020, Journal of the American Society of Nephrology : JASN.

[30]  Jungsang Ryou,et al.  Seroprevalence of Anti-SARS-CoV-2 Antibodies among Outpatients in Southwestern Seoul, Korea , 2020, Journal of Korean medical science.

[31]  Daniel J. Nesbitt,et al.  Low Seroprevalence of SARS-CoV-2 in Rhode Island Blood Donors Determined using Multiple Serological Assay Formats , 2020, medRxiv.

[32]  T. Fujiwara,et al.  Seroprevalence of SARS-CoV-2 IgG Antibodies in Utsunomiya City, Greater Tokyo, after first pandemic in 2020 (U-CORONA): a household- and population-based study , 2020, medRxiv.

[33]  Brian E. Dixon,et al.  Population Point Prevalence of SARS-CoV-2 Infection Based on a Statewide Random Sample — Indiana, April 25–29, 2020 , 2020, MMWR. Morbidity and mortality weekly report.

[34]  Nicholas P. Deputy,et al.  Estimated Community Seroprevalence of SARS-CoV-2 Antibodies — Two Georgia Counties, April 28–May 3, 2020 , 2020, MMWR. Morbidity and mortality weekly report.

[35]  R. Walensky,et al.  Serosurveillance and the COVID-19 Epidemic in the US: Undetected, Uncertain, and Out of Control. , 2020, JAMA.

[36]  Kathryn T. Morrison,et al.  High Community SARS-CoV-2 Antibody Seroprevalence in a Ski Resort Community, Blaine County, Idaho, US. Preliminary Results , 2020, medRxiv.

[37]  E. Berényi,et al.  Novel coronavirus epidemic in the Hungarian population, a cross-sectional nationwide survey to support the exit policy in Hungary , 2020, GeroScience.

[38]  A. Scherag,et al.  Seroprevalence of SARS-CoV-2 antibodies in an entirely PCR-sampled and quarantined community after a COVID-19 outbreak - the CoNAN study , 2020, medRxiv.

[39]  A. Dalpke,et al.  Anti-SARS-CoV-2 IgG antibodies in adolescent students and their teachers in Saxony, Germany (SchoolCoviDD19): very low seropraevalence and transmission rates , 2020, medRxiv.

[40]  D. Lee,et al.  IgG Seroprevalence of COVID-19 among Individuals without a History of the Coronavirus Disease Infection in Daegu, Korea , 2020, Journal of Korean medical science.

[41]  D. Skowronski,et al.  Low SARS-CoV-2 sero-prevalence based on anonymized residual sero-survey before and after first wave measures in British Columbia, Canada, March-May 2020 , 2020, medRxiv.

[42]  P. Glasziou,et al.  Estimating the seroprevalence of SARS-CoV-2 infections: systematic review , 2020, medRxiv.

[43]  J. Izopet,et al.  The real seroprevalence of SARS-CoV-2 in France and its consequences for virus dynamics , 2020, Scientific Reports.

[44]  M. Hernán,et al.  Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study , 2020, The Lancet.

[45]  Kana Yamamoto,et al.  Geographical Profiles of COVID-19 Outbreak in Tokyo: An Analysis of the Primary Care Clinic–Based Point-of-Care Antibody Testing , 2020, Journal of primary care & community health.

[46]  C. Knabbe,et al.  SARS-CoV-2 IgG seroprevalence in blood donors located in three different federal states, Germany, March to June 2020 , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[47]  H. V. Bakel,et al.  Seroconversion of a city: Longitudinal monitoring of SARS-CoV-2 seroprevalence in New York City , 2020, medRxiv.

[48]  C. Reed,et al.  Seroprevalence of Antibodies to SARS-CoV-2 in Six Sites in the United States, March 23-May 3, 2020 , 2020, medRxiv.

[49]  A. Giacomelli,et al.  Seroprevalence of SARS-CoV-2 IgG significantly varies with age: results from a mass population screening (SARS-2-SCREEN-CdA). , 2020, medRxiv.

[50]  S. Lee,et al.  Antibody Responses to SARS-CoV-2 at 8 Weeks Postinfection in Asymptomatic Patients , 2020, Emerging infectious diseases.

[51]  Christel Faes,et al.  Belgian Covid-19 Mortality, Excess Deaths, Number of Deaths per Million, and Infection Fatality Rates (8 March - 9 May 2020) , 2020, medRxiv.

[52]  M. Margaglione,et al.  FAR AWAY FROM HERD IMMUNITY TO SARS-CoV-2: results from a survey in healthy blood donors in South Eastern Italy , 2020, medRxiv.

[53]  S. Lauer,et al.  Serology-informed estimates of SARS-COV-2 infection fatality risk in Geneva, Switzerland , 2020, medRxiv.

[54]  A. Flahault,et al.  Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study , 2020, The Lancet.

[55]  A. von Eckardstein,et al.  Population-wide evolution of SARS-CoV-2 immunity tracked by a ternary immunoassay , 2020, medRxiv.

[56]  T. Matsumura,et al.  Challenges of community point-of-care antibody testing for COVID-19 herd-immunity in Japan , 2020, QJM : monthly journal of the Association of Physicians.

[57]  J. Núñez,et al.  The Effect of Age on Mortality in Patients With COVID-19: A Meta-Analysis With 611,583 Subjects , 2020, Journal of the American Medical Directors Association.

[58]  S. Ciesek,et al.  Epidemiological study to detect active SARS-CoV-2 infections and seropositive persons in a selected cohort of employees in the Frankfurt am Main metropolitan area , 2020, medRxiv.

[59]  P. Horby,et al.  Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study , 2020, BMJ.

[60]  Kristen M J Azar,et al.  Disparities In Outcomes Among COVID-19 Patients In A Large Health Care System In California. , 2020, Health affairs.

[61]  J. Ioannidis,et al.  The infection fatality rate of COVID-19 inferred from seroprevalence data , 2020, medRxiv.

[62]  R. Krüger,et al.  Prevalence of SARS-CoV-2 infection in the Luxembourgish population: the CON-VINCE study. , 2020, medRxiv.

[63]  S. Bosari,et al.  SARS-CoV-2 seroprevalence trends in healthy blood donors during the COVID-19 Milan outbreak , 2020, medRxiv.

[64]  M. Nöthen,et al.  Infection fatality rate of SARS-CoV-2 infection in a German community with a super-spreading event , 2020 .

[65]  M. Wener,et al.  Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in Boise, Idaho , 2020, Journal of Clinical Microbiology.

[66]  Akihide Ryo,et al.  Interpreting Diagnostic Tests for SARS-CoV-2. , 2020, JAMA.

[67]  G. Meyerowitz-Katz,et al.  A systematic review and meta-analysis of published research data on COVID-19 infection fatality rates , 2020, International Journal of Infectious Diseases.

[68]  K. Iwata,et al.  Estimation of seroprevalence of novel coronavirus disease (COVID-19) using preserved serum at an outpatient setting in Kobe, Japan: A cross-sectional study , 2020, Clinical Epidemiology and Global Health.

[69]  Simon J. More,et al.  Inferred duration of infectious period of SARS-CoV-2: rapid scoping review and analysis of available evidence for asymptomatic and symptomatic COVID-19 cases , 2020, BMJ Open.

[70]  C. Reusken,et al.  Herd immunity is not a realistic exit strategy during a COVID-19 outbreak , 2020 .

[71]  X. Tang,et al.  Antibody responses to SARS-CoV-2 in patients with COVID-19 , 2020, Nature Medicine.

[72]  Jens K. Boldsen,et al.  Estimation of SARS-CoV-2 Infection Fatality Rate by Real-time Antibody Screening of Blood Donors , 2020, medRxiv.

[73]  Eun Ji Kim,et al.  Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. , 2020, JAMA.

[74]  D. Larremore,et al.  Estimating SARS-CoV-2 seroprevalence and epidemiological parameters with uncertainty from serological surveys , 2020, medRxiv.

[75]  E. Lavezzo,et al.  Suppression of COVID-19 outbreak in the municipality of Vo, Italy , 2020, medRxiv.

[76]  P. Gallian,et al.  Cluster of COVID-19 in northern France: A retrospective closed cohort study , 2020, medRxiv.

[77]  J. Ioannidis,et al.  COVID-19 antibody seroprevalence in Santa Clara County, California , 2020, medRxiv.

[78]  Jordan J. Clark,et al.  Detection of neutralising antibodies to SARS-CoV-2 to determine population exposure in Scottish blood donors between March and May 2020 , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[79]  Kari Stefansson,et al.  Spread of SARS-CoV-2 in the Icelandic Population , 2020, The New England journal of medicine.

[80]  A. Mirzazadeh,et al.  Epidemiological characteristics of COVID-19: a systematic review and meta-analysis , 2020, Epidemiology and Infection.

[81]  Francesca Molinari,et al.  Estimating the COVID-19 infection rate: Anatomy of an inference problem , 2020, Journal of Econometrics.

[82]  Christl A. Donnelly,et al.  Estimates of the severity of coronavirus disease 2019: a model-based analysis , 2020, The Lancet Infectious Diseases.

[83]  G. Chowell,et al.  Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020 , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[84]  Hiroshi Nishiura,et al.  The Rate of Underascertainment of Novel Coronavirus (2019-nCoV) Infection: Estimation Using Japanese Passengers Data on Evacuation Flights , 2020, Journal of clinical medicine.

[85]  Andrea Benedetti,et al.  Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis , 2020, BMJ.

[86]  Å. Lundkvist,et al.  Pronounced difference in Covid-19 antibody prevalence indicates cluster transmission in Stockholm, Sweden , 2020, Infection ecology & epidemiology.

[87]  R. Magalhães,et al.  Heterogeneous and Dynamic Prevalence of Asymptomatic Influenza Virus Infections , 2016, Emerging infectious diseases.

[88]  S. Lattimore,et al.  Blood donors in England and North Wales: demography and patterns of donation , 2015, Transfusion.

[89]  David J Spiegelhalter,et al.  A re-evaluation of random-effects meta-analysis , 2009, Journal of the Royal Statistical Society. Series A,.

[90]  J. Higgins,et al.  Meta-Regression in Stata , 2008 .

[91]  Ruth B. Greenberg,et al.  University of Louisville School of Medicine , 2004, Academic medicine : journal of the Association of American Medical Colleges.

[92]  F. Eugene Yates,et al.  The national center for health statistics , 1973, Annals of Biomedical Engineering.

[93]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.

[94]  N. Crepaz,et al.  Higher incidence of clear cell adenocarcinoma of the cervix and vagina among women born between 1947 and 1971 in the United States , 2011, Cancer Causes & Control.

[95]  P. Tüll,et al.  European Centre for Disease Prevention and Control , 2006 .

[96]  S. Haeghebaert,et al.  BULLETIN EUROPÉEN SUR LES MALADIES TRANSMISSIBLES / EUROPEAN COMMUNICABLE DISEASE BULLETIN , 2003 .

[97]  T. Taufa,et al.  Health statistics. , 1986, Papua and New Guinea medical journal.

[98]  B. Gladen,et al.  Estimating prevalence from the results of a screening test. , 1978, American journal of epidemiology.